Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Advertisement

Advertisement




Aug
13
Today In Oncology
Darolutamide Plus Goserelin in AR-Positive Salivary Gland Carcinoma
Does ctDNA-Guided Surveillance Improve Curative Treatment Rates in Resected Colorectal Cancer?
Immune Cell Dysfunction Not Absence Defines Nonmelanoma Skin Cancer in Immunosuppressed Patients
ASTRO Updates Guideline on Radiation Therapy for Pancreatic Cancer
Residential Social Vulnerability Associated With Worse Survival Among Black Women With Epithelial Ovarian Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo